Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

13.1%

11 terminated/withdrawn out of 84 trials

Success Rate

81.7%

-4.9% vs industry average

Late-Stage Pipeline

5%

4 trials in Phase 3/4

Results Transparency

18%

9 of 49 completed trials have results

Key Signals

10 recruiting9 with results10 terminated

Enrollment Performance

Analytics

Phase 1
66(78.6%)
Phase 2
13(15.5%)
Phase 3
3(3.6%)
Phase 4
1(1.2%)
N/A
1(1.2%)
84Total
Phase 1(66)
Phase 2(13)
Phase 3(3)
Phase 4(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (84)

Showing 20 of 84 trials
NCT07670312Phase 1Recruiting

Evaluation of XYA02 in Patients With Advanced Solid Tumors

Role: collaborator

NCT07785193Phase 1Not Yet Recruiting

A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid Tumors

Role: collaborator

NCT07235293Phase 2Recruiting

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Role: collaborator

NCT06717100Phase 1Completed

Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib

Role: collaborator

NCT07732387Phase 1Not Yet Recruiting

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline

Role: collaborator

NCT06557499Not ApplicableCompleted

A 3-way Crossover Clinical Investigation to Assess the Performance of Two Different Sized Polyurethane Condoms Versus a Latex Condom in Healthy Monogamous Couples.

Role: collaborator

NCT06429930Phase 1Recruiting

Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults

Role: collaborator

NCT07675668Phase 2Not Yet Recruiting

Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy

Role: collaborator

NCT04652518Phase 2Terminated

LYT-100 in Post-acute COVID-19 Respiratory Disease

Role: collaborator

NCT05876312Phase 1Recruiting

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Role: collaborator

NCT07595393Phase 2Not Yet Recruiting

A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade

Role: collaborator

NCT05951049Phase 2Active Not Recruiting

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Role: collaborator

NCT07219771Phase 3Recruiting

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

Role: collaborator

NCT07401121Phase 1Recruiting

Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

Role: collaborator

NCT05491421Phase 1Completed

A Study of ZT002 in Healthy Participants

Role: collaborator

NCT05957081Phase 1Recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309

Role: collaborator

NCT05288543Phase 1Terminated

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Role: collaborator

NCT06279871Phase 3Completed

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

Role: collaborator

NCT06961565Phase 1Recruiting

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Role: collaborator

NCT06125691Phase 1Completed

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Role: collaborator